Blood cancers, such as leukemia, lymphoma, myeloma or myelodysplastic syndromes, can affect the bone marrow, blood cells, lymph nodes and other parts of the lymphatic system.

An estimated 1,237,824 people in the US are either living with, or are in remission from, leukemia, lymphoma or myeloma.

**Leukemia**
- An estimated 345,422 people are either living with, or in remission from, leukemia in the US.
- Leukemia causes more deaths than any other cancer among children, adolescents and young adults younger than 20 years.
- More males than females are diagnosed with leukemia and die of leukemia.

**Hodgkin and Non-Hodgkin Lymphoma**
- An estimated 788,939 people are either living with, or in remission from, lymphoma in the US.
- An estimated 181,967 people are either living with, or are in remission from, Hodgkin lymphoma (HL).
- An estimated 606,972 people are either living with, or are in remission from, non-Hodgkin lymphoma (NHL).
- The five-year relative survival rate for patients with HL has more than doubled from 40 percent in the early 1960s to 88.3 percent from 2005 to 2011.
- The five-year relative survival rate for NHL patients rose from 31 percent in the early 1960s to 71.9 percent from 2005 to 2011.

**Myeloma**
- An estimated 103,463 people are either living with, or in remission from, myeloma in the US.
- The median age at diagnosis is 69 years; myeloma is seldom diagnosed in people under age 40.
- The incidence of myeloma in blacks was 139.3 percent greater than myeloma incidence in whites in 2012.
- Overall, mortality from myeloma decreased from 2003 to 2012 (the most recent data available).

**Myelodysplastic Syndromes (MDS)**
- There were an estimated 15,148 new cases of myelodysplastic syndromes (MDS) diagnosed each year from 2008 to 2012.
- The estimated overall incidence rate of MDS is 5.0 cases per 100,000 population. White males have the highest MDS incidence rates (7.0 per 100,000 population).
The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to lifesaving therapies for all blood cancer patients with one goal in mind: A world without blood cancers.


New effective therapies, once unimaginable, are saving the lives of blood cancer patients today, not someday.

Finding Cures
LLS-funded research has led to the discovery and development of lifesaving therapies, including targeted therapies that selectively kill cancer cells and immunotherapy drugs that help a patient’s immune system destroy cancer cells.

Since 1954, LLS has invested more than $1 billion in blood cancer research.

Some of the therapies first approved for blood cancer patients are now helping patients with different types of cancers and other serious diseases.

Ensuring Access
LLS is the leading source of free blood cancer information, education and support, helping patients in their communities through our chapters across the US and Canada.

LLS is the voice for all blood cancer patients, advocating for policies that accelerate the approval of new blood cancer treatments and ensure patient access to quality, affordable and coordinated care.

To find the nearest LLS chapter or obtain more information, call one of our Information Specialists at (800) 955-4572, Monday through Friday, 9 am to 9 pm ET, or visit www.LLS.org.